{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:10:29Z","timestamp":1781478629794,"version":"3.54.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ecl.2019.02.001","type":"journal-article","created":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T03:24:42Z","timestamp":1553311482000},"page":"341-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Transfeminine Hormone Therapy"],"prefix":"10.1016","volume":"48","author":[{"given":"Oksana","family":"Hamidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J.","family":"Davidge-Pitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ecl.2019.02.001_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/15532739.2011.700873","article-title":"Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7","volume":"13","author":"Coleman","year":"2012","journal-title":"Int J Transgend"},{"issue":"11","key":"10.1016\/j.ecl.2019.02.001_bib2","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an endocrine society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2019.02.001_bib3","doi-asserted-by":"crossref","first-page":"e16885","DOI":"10.1371\/journal.pone.0016885","article-title":"Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden","volume":"6","author":"Dhejne","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ecl.2019.02.001_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-2265.2009.03625.x","article-title":"Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes","volume":"72","author":"Murad","year":"2010","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2019.02.001_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11154-018-9459-y","article-title":"Quality of life of treatment-seeking transgender adults: a systematic review and meta-analysis","volume":"19","author":"Nobili","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.ecl.2019.02.001_bib6","doi-asserted-by":"crossref","first-page":"8684625","DOI":"10.1155\/2018\/8684625","article-title":"Quality of life in transitioned trans persons: a retrospective cross-sectional cohort study","volume":"2018","author":"Jellestad","year":"2018","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.ecl.2019.02.001_bib7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1210\/jc.2017-01927","article-title":"Breast development in transwomen after 1 year of cross-sex hormone therapy: results of a prospective multicenter study","volume":"103","author":"de Blok","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ecl.2019.02.001_bib8","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1210\/jc.2012-2030","article-title":"Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens","volume":"97","author":"Seal","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2019.02.001_bib9","first-page":"1240","article-title":"Clinical review: Breast development in trans women receiving cross-sex hormones","volume":"11","author":"Wierckx","year":"2014","journal-title":"J\u00a0Sex Med"},{"issue":"10042","key":"10.1016\/j.ecl.2019.02.001_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(16)00682-6","article-title":"Serving transgender people: clinical care considerations and service delivery models in transgender health","volume":"388","author":"Wylie","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ecl.2019.02.001_bib11","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1210\/jc.2015-2237","article-title":"Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis","volume":"100","author":"Mohammed","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2019.02.001_bib12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0029-7844(96)00513-3","article-title":"Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17\u03b2-estradiol","volume":"89","author":"Price","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ecl.2019.02.001_bib13","series-title":"Drug & device selection in heart failure","author":"Deedwania","year":"2014"},{"issue":"6","key":"10.1016\/j.ecl.2019.02.001_bib14","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1365-2125.2011.04031.x","article-title":"Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study","volume":"72","author":"Gil","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"23","key":"10.1016\/j.ecl.2019.02.001_bib15","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMc071938","article-title":"Growth of a meningioma in a transsexual patient after estrogen\u2013progestin therapy","volume":"357","author":"Gazzeri","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2019.02.001_bib16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jama.2012.165234","article-title":"Management of transgenderism","volume":"309","author":"Spack","year":"2013","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.ecl.2019.02.001_bib17","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ecl.2019.02.001_bib18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-2005-865900","article-title":"Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist","volume":"113","author":"Dittrich","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"10.1016\/j.ecl.2019.02.001_bib19","first-page":"55","article-title":"Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals","volume":"2","author":"Weinand","year":"2015","journal-title":"J\u00a0Clin Transl Endocrinol"},{"issue":"8","key":"10.1016\/j.ecl.2019.02.001_bib20","first-page":"2012","article-title":"Conjectures concerning cross-sex hormone treatment of aging transsexual persons","volume":"11","author":"Gooren","year":"2014","journal-title":"J\u00a0Sex Med"},{"issue":"6","key":"10.1016\/j.ecl.2019.02.001_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.med.0000436184.42554.b7","article-title":"Transgenderism and reproduction","volume":"20","author":"T'Sjoen","year":"2013","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"10.1016\/j.ecl.2019.02.001_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/09540261.2015.1084275","article-title":"Fertility options in transgender people","volume":"28","author":"De Roo","year":"2016","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.ecl.2019.02.001_bib23","series-title":"Principles of transgender medicine and surgery","author":"Ettner","year":"2016"},{"issue":"2","key":"10.1016\/j.ecl.2019.02.001_bib24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ajh.24593","article-title":"Thrombotic issues in transgender medicine: a review","volume":"92","author":"Shatzel","year":"2017","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.ecl.2019.02.001_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2265.1997.2601068.x","article-title":"Mortality and morbidity in transsexual subjects treated with cross-sex hormones","volume":"47","author":"Van Kesteren","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"10.1016\/j.ecl.2019.02.001_bib26","first-page":"2641","article-title":"Long-term evaluation of cross-sex hormone treatment in transsexual persons","volume":"9","author":"Wierckx","year":"2012","journal-title":"J\u00a0Sex Med"},{"issue":"1","key":"10.1016\/j.ecl.2019.02.001_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1210\/jc.2007-1809","article-title":"Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience","volume":"93","author":"Gooren","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2019.02.001_bib28","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.fertnstert.2008.12.017","article-title":"Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy","volume":"93","author":"Ott","year":"2010","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.ecl.2019.02.001_bib29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/AOG.0000000000000692","article-title":"Effects of cross-sex hormone treatment on transgender women and men","volume":"125","author":"Deutsch","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ecl.2019.02.001_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M17-2785","article-title":"Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study","volume":"169","author":"Getahun","year":"2018","journal-title":"Ann Intern Med"},{"issue":"7655","key":"10.1016\/j.ecl.2019.02.001_bib31","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bmj.39555.441944.BE","article-title":"Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis","volume":"336","author":"Canonico","year":"2008","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ecl.2019.02.001_bib32","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1210\/jc.2017-01643","article-title":"Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis","volume":"102","author":"Maraka","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2019.02.001_bib33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1530\/EJE-13-0493","article-title":"Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case\u2013control study","volume":"169","author":"Wierckx","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.ecl.2019.02.001_bib34","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2265.2003.01753.x","article-title":"Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects","volume":"58","author":"Elbers","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"10.1016\/j.ecl.2019.02.001_bib35","first-page":"1999","article-title":"Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the E uropean N etwork for the I nvestigation of G ender I ncongruence","volume":"11","author":"Wierckx","year":"2014","journal-title":"J\u00a0Sex Med"},{"issue":"5","key":"10.1016\/j.ecl.2019.02.001_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.endonu.2015.02.001","article-title":"Effect of cross-sex hormone treatment on cardiovascular risk factors in transsexual individuals. Experience in a specialized unit in Catalonia","volume":"62","author":"Quir\u00f3s","year":"2015","journal-title":"Endocrinol Nutr"},{"issue":"4","key":"10.1016\/j.ecl.2019.02.001_bib37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jpsychores.2015.02.001","article-title":"Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: a 2 year follow-up study","volume":"78","author":"Colizzi","year":"2015","journal-title":"J\u00a0Psychosomatic Res"},{"issue":"9","key":"10.1016\/j.ecl.2019.02.001_bib38","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0026-0495(89)90233-3","article-title":"Mortality and morbidity in transsexual patients with cross-gender hormone treatment","volume":"38","author":"Asscheman","year":"1989","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.ecl.2019.02.001_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF01542220","article-title":"Physical and hormonal evaluation of transsexual patients: a longitudinal study","volume":"15","author":"Meyer","year":"1986","journal-title":"Arch Sex Behav"},{"issue":"4","key":"10.1016\/j.ecl.2019.02.001_bib40","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/EJE-10-1038","article-title":"A\u00a0long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones","volume":"164","author":"Asscheman","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2019.02.001_bib41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/lgbt.2014.0050","article-title":"Mortality among veterans with transgender-related diagnoses in the veterans health administration, FY2000\u20132009","volume":"1","author":"Blosnich","year":"2014","journal-title":"LGBT Health"},{"issue":"7\u20138","key":"10.1016\/j.ecl.2019.02.001_bib42","doi-asserted-by":"crossref","first-page":"E544","DOI":"10.5489\/cuaj.175","article-title":"Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy","volume":"7","author":"Turo","year":"2013","journal-title":"Can Urol Assoc J"},{"issue":"5","key":"10.1016\/j.ecl.2019.02.001_bib43","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1046\/j.1464-410x.1998.00582.x","article-title":"Metastatic prostatic carcinoma in a male-to-female transsexual","volume":"81","author":"Haarst","year":"1998","journal-title":"Br J Urol"},{"issue":"5","key":"10.1016\/j.ecl.2019.02.001_bib44","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3816\/CGC.2007.n.016","article-title":"Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient","volume":"5","author":"Dorff","year":"2007","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2019.02.001_bib45","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1464-410X.1994.tb07503.x","article-title":"Carcinoma of the prostate in a transsexual","volume":"73","author":"Thurston","year":"1994","journal-title":"Br J Urol"},{"issue":"10","key":"10.1016\/j.ecl.2019.02.001_bib46","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/and.12208","article-title":"Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens","volume":"46","author":"Gooren","year":"2014","journal-title":"Andrologia"},{"issue":"3","key":"10.1016\/j.ecl.2019.02.001_bib47","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11154-018-9449-0","article-title":"Endocrine treatment of aging transgender people","volume":"19","author":"Gooren","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"10.1016\/j.ecl.2019.02.001_bib48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10549-014-3213-2","article-title":"Incidence of breast cancer in a cohort of 5,135 transgender veterans","volume":"149","author":"Brown","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ecl.2019.02.001_bib49","unstructured":"de Blok Christel J, Wiepjes CM, Nota NM, et\u00a0al. Breast cancer in transgender persons receiving gender affirming hormone treatment: results of a nationwide cohort study. Paper presented at: 20th European Congress of Endocrinology. Barcelona, Spain, May 19, 2018."},{"issue":"10","key":"10.1016\/j.ecl.2019.02.001_bib50","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/and.12399","article-title":"Five new cases of breast cancer in transsexual persons","volume":"47","author":"Gooren","year":"2015","journal-title":"Andrologia"},{"issue":"12","key":"10.1016\/j.ecl.2019.02.001_bib51","first-page":"3129","article-title":"Breast cancer development in transsexual subjects receiving cross-sex hormone treatment","volume":"10","author":"Gooren","year":"2013","journal-title":"J\u00a0Sex Med"},{"issue":"6","key":"10.1016\/j.ecl.2019.02.001_bib52","doi-asserted-by":"crossref","first-page":"W735","DOI":"10.2214\/AJR.14.12723","article-title":"Breast cancer in male-to-female transsexuals: use of breast imaging for detection","volume":"203","author":"Maglione","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ecl.2019.02.001_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.steroids.2014.12.010","article-title":"Estrogen and bone health in men and women","volume":"99","author":"Cauley","year":"2015","journal-title":"Steroids"},{"issue":"3","key":"10.1016\/j.ecl.2019.02.001_bib54","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2265.1998.00396.x","article-title":"Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones","volume":"48","author":"Van Kesteren","year":"1998","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2019.02.001_bib55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00198-014-2805-3","article-title":"Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study","volume":"26","author":"Van Caenegem","year":"2015","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.ecl.2019.02.001_bib56","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bone.2013.01.039","article-title":"Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy","volume":"54","author":"Van Caenegem","year":"2013","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.ecl.2019.02.001_bib57","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1210\/jc.2017-01642","article-title":"Effect of sex steroids on the bone health of transgender individuals: a systematic review and meta-analysis","volume":"102","author":"Singh-Ospina","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2019.02.001_bib58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-8587(16)30319-9","article-title":"Oestrogen and anti-androgen therapy for transgender women","volume":"5","author":"Tangpricha","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2019.02.001_bib59","doi-asserted-by":"crossref","first-page":"e12666","DOI":"10.1111\/and.12666","article-title":"Prolactin levels during short-and long-term cross-sex hormone treatment: an observational study in transgender persons","volume":"49","author":"Nota","year":"2017","journal-title":"Andrologia"},{"issue":"5","key":"10.1016\/j.ecl.2019.02.001_bib60","first-page":"562","article-title":"Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study","volume":"118","author":"Kovacs","year":"1994","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.ecl.2019.02.001_bib61","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/and.12317","article-title":"Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy","volume":"47","author":"Cunha","year":"2015","journal-title":"Andrologia"},{"issue":"5","key":"10.1016\/j.ecl.2019.02.001_bib62","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1089\/lgbt.2016.0190","article-title":"Transient elevated serum prolactin in trans women is caused by cyproterone acetate treatment","volume":"4","author":"Defreyne","year":"2017","journal-title":"LGBT Health"},{"issue":"11","key":"10.1016\/j.ecl.2019.02.001_bib63","first-page":"1765","article-title":"Differential effects of cyproterone acetate vs spironolactone on serum high-density lipoprotein and prolactin concentrations in the hormonal treatment of transgender women","volume":"13","author":"Fung","year":"2016","journal-title":"J\u00a0Sex Med"},{"issue":"6","key":"10.1016\/j.ecl.2019.02.001_bib64","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.ecl.2019.02.001_bib65","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","article-title":"Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial","volume":"289","author":"Chlebowski","year":"2003","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.ecl.2019.02.001_bib66","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.289.20.2673","article-title":"Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial","volume":"289","author":"Wassertheil-Smoller","year":"2003","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ecl.2019.02.001_bib67","first-page":"279","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy","volume":"30","author":"Patterson","year":"2004","journal-title":"BMJ Sex Reprod Health"},{"key":"10.1016\/j.ecl.2019.02.001_bib68","doi-asserted-by":"crossref","first-page":"c2519","DOI":"10.1136\/bmj.c2519","article-title":"Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study","volume":"340","author":"Renoux","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ecl.2019.02.001_bib69","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/M17-0577","article-title":"Cardiovascular disease among transgender adults receiving hormone therapy: a narrative review","volume":"167","author":"Streed","year":"2017","journal-title":"Ann Intern Med"},{"issue":"25 Part B","key":"10.1016\/j.ecl.2019.02.001_bib70","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ecl.2019.02.001_bib71","article-title":"Hormone therapy for preventing cardiovascular disease in post-menopausal women","author":"Boardman","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ecl.2019.02.001_bib72","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1161\/STROKEAHA.116.013052","article-title":"Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen","volume":"47","author":"Canonico","year":"2016","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.ecl.2019.02.001_bib73","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/PRS.0000000000001155","article-title":"Obesity is associated with increased health care charges in patients undergoing outpatient plastic surgery","volume":"135","author":"Sieffert","year":"2015","journal-title":"Plast Reconstr Surg"},{"issue":"18","key":"10.1016\/j.ecl.2019.02.001_bib74","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1097\/00002030-200012220-00024","article-title":"HIV prevalence and incidence among male-to-female transsexuals receiving HIV prevention services in Los Angeles County","volume":"14","author":"Simon","year":"2000","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.ecl.2019.02.001_bib75","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00126334-200112010-00012","article-title":"Incidence of human immunodeficiency virus among male-to-female transgendered persons in San Francisco","volume":"28","author":"Kellogg","year":"2001","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"3S2","key":"10.1016\/j.ecl.2019.02.001_bib76","doi-asserted-by":"crossref","first-page":"20810","DOI":"10.7448\/IAS.19.3.20810","article-title":"Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices","volume":"19","author":"Radix","year":"2016","journal-title":"J\u00a0Int AIDS Soc"},{"key":"10.1016\/j.ecl.2019.02.001_bib77","series-title":"Tom Waddell Health Center protocols for hormonal reassignment of gender","author":"Davidson","year":"2013"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852919300064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852919300064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:43:54Z","timestamp":1760175834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852919300064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0889852919300064"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2019.02.001","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transfeminine Hormone Therapy","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2019.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}